XARELTO® is the only new oral anticoagulant with FDA approval in this indication Raritan, NJ (July 1, 2011) /PRNewswire/ - Janssen Pharmaceuticals, Inc. announced today that the U.S. Food and Drug ...

Aurobindo has obtained the Food and Drug Administration’s green light for rivaroxaban tablets, 2.5 mg, which is the generic of Janssen’s Xarelto. Rivaroxaban tablets are used to reduce the risk of ...

Lupin is introducing rivaroxaban tablets, 2.5 mg, which is the generic of Janssen’s Xarelto. The medication is used to reduce the risk of major cardiovascular events in patients with coronary artery ...

A new oral suspension formulation of Xarelto has also been approved by the FDA. The Food and Drug Administration (FDA) has approved Xarelto ® (rivaroxaban) for 2 new pediatric indications: treatment ...

Please provide your email address to receive an email when new articles are posted on . Xarelto was superior to aspirin for lowering the risk for recurrent stroke or systemic embolism among ...

RARITAN, N.J., July 8, 2019 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new results from the Phase 3 EINSTEIN-Jr study, showing pediatric patients (aged ...

XARELTO (rivaroxaban) 20mg tablets Janssen Pharmaceuticals announced FDA approval of Xarelto (rivaroxaban) tablets for the prevention of deep vein thrombosis (DVT) that may lead to a pulmonary ...

Raritan, NJ (September 8, 2011) — Johnson & Johnson Pharmaceutical Research and Development, L.L.C. (J&JPRD) announced today that the U.S. Food and Drug Administration’s (FDA) Cardiovascular and Renal ...

RARITAN, N.J., May 16, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today presented new data from the Phase 3 VOYAGER PAD study which showed XARELTO ® (rivaroxaban) ...

For patients who have undergone successful catheter ablation for atrial fibrillation, treatment with rivaroxaban does not offer superior stroke protection versus aspirin.

Two of three commonly prescribed non-vitamin K oral anticoagulants (NOACs)—dabigatran and apixaban—have similar rates of major bleeding compared with aspirin, a large systematic review and ...

Johnson & Johnson and Bayer’s Xarelto, gradually losing share to Pfizer and Bristol-Myers Squibb’s Eliquis, just won a much-needed new indication analysts figure is worth $1.5 billion in the U.S.